CAS 916850-24-3 EGFRvIIIpeptide

Send Inquiry
CAS 916850-24-3 EGFRvIIIpeptide
Details
EGFR type-III deletion mutant neo-epitope;
Category: Tumor-specific neo-epitope / glioma mutation peptide.
Peptide Purity (HPLC) ≥95%
CAS No. 916850-24-3
Structure Linear tumor neo-epitope (EGFRvIII)
Solubility Water, dilute acetic acid/DMSO, PBS
Storage Powder, −20°C, dry, light-protected
Category
Epitope Peptides
Share to
Description

Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 916850-24-3 egfrviiipeptide in China, also supports custom service. Welcome to wholesale bulk high quality cas 916850-24-3 egfrviiipeptide from our factory. Contact us for more details.

 

Description The tumor-specific junctional sequence of EGFRvIII absent from normal tissue; a core target for glioblastoma-specific vaccines and CAR-T.

 

Product Basic Information Table

 

Product Standard English Name Product Abbreviation / Alias Function Tags (comma-separated) Core Structure Molecular Formula Exact Mass (Da) Average MW (Da) Salt Form Length (aa)
EGFRvIII peptide (LEEKKGNYV, 9-mer, EGFRvIII fusion-junction MHC-I epitope) EGFRvIII epitope; LEEKKGNYV; EGFR mutant junction peptide; short PEPvIII epitope EGFRvIII, tumor-specific mutation, MHC-I epitope, glioblastoma, cancer vaccine, immunogenic peptide, CTL epitope, neoantigen, brain tumor, dendritic cell vaccine, Flagellin adjuvant, immunotherapy Full sequence H-Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-OH; single-letter LEEKKGNYV, 9 aa; free N-terminal amine and free C-terminal carboxyl (free acid); linear peptide, no artificial modifications; C-terminus is Val (not Cys) - distinct from the 14-mer KLH-conjugatable PEPvIII. Sensitive residues: Tyr x1 (light-sensitive); no free Cys, no Met, no Trp. C48H78N12O16 1078.57 1079.22 TFA salt (Immunomart lists C48H78N12O16.xCF3COOH); other vendors list free peptide; confirm on COA 9

 

Physicochemical Solubility & Storage Parameters

 

Product Code Appearance Long-term Storage Short-term Storage Solution Stability Solid Powder Stability
PEP-EGFRVIII-01 White to off-white powder (TFA salt) Store desiccated, light-protected and sealed at <= -20 C; expected powder stability 2-3 years After reconstitution, aliquot into single-use portions and store at -80 C; avoid repeated freeze-thaw Protect from light due to Tyr. The peptide is amphipathic (acidic Glu and basic Lys); soluble in sterile water or PBS, pre-dissolve in a small amount of DMSO if sparingly soluble, then dilute; gentle sonication helps. Keep powder dry, light-protected and sealed. No free thiol or methionine, so oxidation risk is low.

 

Functional Description

 

Product Code Frontend Short Summary Detailed Biological Function Description Applicable Research Areas (comma-separated) Targets / Receptors
PEP-EGFRVIII-01 EGFRvIII peptide (CAS 916850-24-3) is the nonapeptide LEEKKGNYV spanning the tumor-specific fusion junction created by the EGFRvIII exon 2-7 deletion. Presented on MHC-I, it elicits specific T-cell immunity against glioblastoma and is studied in cancer vaccines, often combined with Flagellin adjuvant. EGFRvIII is a constitutively active, ligand-independent EGFR mutant generated by an in-frame 801-bp deletion of exons 2-7 (removing residues 6-273 of the extracellular domain). The deletion junction creates a novel glycine and a tumor-unique sequence absent from normal tissues, yet present in ~30% of glioblastomas and subsets of lung, breast and head-and-neck cancers, making it an ideal tumor-specific therapeutic target. The product registered under CAS 916850-24-3 is the junction-spanning nonapeptide LEEKKGNYV, which is presented on MHC class I and recognized by specific CD8+ T cells. Studies show this peptide, alone or combined with Flagellin B adjuvant, can induce apoptosis and trigger specific immune responses against glioblastoma; it is used for in vitro priming of EGFRvIII-specific T cells, APC pulsing and neoantigen vaccine research. Important distinction: the 14-mer PEPvIII used in the clinical vaccine rindopepimut (CDX-110) is LEEKKGNYVVTDHC, which carries an extra C-terminal cysteine for KLH conjugation, CAS 129112-17-0, MW ~1634.8 - different from this 9-mer with a free Val C-terminus. tumor immunology, glioblastoma, neoantigen, MHC-I epitope, cancer vaccine, dendritic cell vaccine, brain tumor, CTL epitope mapping, immunotherapy, adjuvant studies MHC class I; EGFRvIII fusion junction; CD8+ T cells

 

 

 

 

Hot Tags: cas 916850-24-3 egfrviiipeptide, China cas 916850-24-3 egfrviiipeptide manufacturers, suppliers, factory, 124454-83-7, 265669-37-2, BCMA72-80, CAS 124454 83 7, CAS 265669 37 2, epitope peptides

Send Inquiry